Key Takeaways
- Thad Huston, CFO and COO of Galapagos, will leave the company on August 1, 2025, to return to the USA.
- Huston joined Galapagos in 2023 to aid its transition toward cell therapy following his tenure at Kite Pharma.
- CEO Paul Stoffels praised Huston’s contributions to the company’s strategic transformation and development of its cell therapy platform.
Leadership Change at Galapagos
Galapagos, a Belgian biotechnology firm, announced that Thad Huston, its Chief Financial Officer and Chief Operating Officer, will depart the company on August 1, 2025. Huston’s decision to leave comes as he plans to return to the United States for personal and professional reasons.
Huston, who joined Galapagos in 2023, played a pivotal role in the company’s shift towards cell therapy. He previously worked at Kite Pharma, before transitioning to Galapagos to provide leadership during a crucial period of transformation. Under his guidance, the company aimed to establish a focused cell therapy business by leveraging a unique decentralized cell therapy platform.
In a statement regarding Huston’s departure, the company’s CEO, Paul Stoffels, commended Huston’s significant contributions, particularly in steering the firm through its strategic overhaul. Stoffels noted, “Thad worked on the transformation of Galapagos into a focused cell therapy business,” highlighting the importance of this phase in the company’s future direction.
Galapagos is currently in the process of selecting a successor for Huston, with an announcement expected in the coming months. This leadership change comes as the company continues to navigate its evolving strategy within the competitive biotechnology landscape.
As the company prepares for this transition, it remains focused on its long-term goals in cell therapy, aiming to position itself as a leader in the field. The leadership stability is crucial for maintaining momentum during this pivotal time, and the appointment of a new CFO/COO will be integral to that effort.
With a commitment to innovation, Galapagos looks forward to building upon Huston’s legacy as it progresses. The company is expected to continue evolving its operations and strategies to capitalize on opportunities in the burgeoning biotechnology sector.
The content above is a summary. For more details, see the source article.